Literature DB >> 2347721

Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion.

M Rotman1, H Aziz, M Porrazzo, K N Choi, M Silverstein, J Rosenthal, G Laungani, R Macchia.   

Abstract

Twenty patients with advanced transitional cell carcinoma of the bladder were treated with radiation and concomitant continuous infusion of 5-fluorouracil with or without Mitomycin. Nineteen of 20 patients were assessed for response. Fourteen of 19 patients (74%) obtained a complete response within 3 to 6 months. An additional three patients (15%) acquired and maintained a complete response after local transurethral resection of the tumor and intravesical chemotherapy, raising the overall complete response (CR) rate to 17/19 (89%). Of the two patients with persistent disease, one is alive and well after salvage cystectomy. Eighteen of 20 patients were evaluated for survival with a median follow-up of 38 months. Seven patients remain alive and well 51 to 78 months, whereas three patients died from intercurrent disease. Eight patients died of either distant metastatic disease (7 patients) or regional disease (1 patient). An adjusted survival calculated by the Life Table Method was 53.6% at 5 years, whereas the overall survival was 39%. The combined modality therapy was well tolerated with no need for treatment interruption or reduction in dose. Late bladder complications include one patient with hemorrhagic cystitis, two patients with dysuria, and two with symptoms of irritable bladder. One patient required a colostomy for a chronic hemorrhagic proctitis. Bladder preservation was achieved in 19/20 patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347721     DOI: 10.1016/0360-3016(90)90449-t

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results.

Authors:  S Birkenhake; S Leykamm; P Martus; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

Review 2.  New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder.

Authors:  P Warde; M K Gospodarowicz
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 3.  Radiation therapy in urinary cancer: state of the art and perspective.

Authors:  M Troiano; P Corsa; A Raguso; S Cossa; M Piombino; G Guglielmi; S Parisi
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

4.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Authors:  Celestia S Higano; Catherine M Tangen; Wael A Sakr; James Faulkner; Saul E Rivkin; Frederick J Meyers; Maha Hussain; Laurence H Baker; Kenneth J Russell; E David Crawford
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

5.  Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.

Authors:  S A Hussain; D D Stocken; D R Peake; J G Glaholm; A Zarkar; D M A Wallace; N D James
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.